Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: An open-label phase i trial

Clinical Cancer Research

Volumn 23, Issue 5, 2017, Pages 1156-1166

  Wang, Chun Meng ^a   Wu, Zhi Qiang ^a   Wang, Yao ^a   Guo, Ye Lei ^a   Dai, Han Ren ^a   Wang, Xiao Hui ^a   Li, Xiang ^a   Zhang, Ya Jing ^a   Zhang, Wen Ying ^a   Chen, Mei Xia ^a   Zhang, Yan ^a   Feng, Kai Chao ^a   Liu, Yang ^a   Li, Su Xia ^a   Yang, Qing Ming ^a   Han, Wei Dong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD3 ANTIGEN; CD30 ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 12P70; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; ANTIBODY CONJUGATE; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 8;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTICLE; AUTOTRANSPLANTATION; CANCER REGRESSION; CELL MIGRATION; CELL THERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DELIRIUM; DISEASE SEVERITY; DIZZINESS; DYSPNEA; FEASIBILITY STUDY; FEMALE; FEVER; GENE DOSAGE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; JOINT SWELLING; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; OPEN STUDY; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; POLYMERASE CHAIN REACTION; REFRACTORY HODGKIN LYMPHOMA; RELAPSED HODGKIN LYMPHOMA; SHIVERING; T LYMPHOCYTE; THROMBOCYTOPENIA; TRANSGENE; TREATMENT RESPONSE; URTICARIA; VOMITING; YOUNG ADULT; BIOLOGICAL THERAPY; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; STEM CELL TRANSPLANTATION; TUMOR RECURRENCE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL- AND TISSUE-BASED THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; KI-1 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ANTIGEN; RECEPTORS, ANTIGEN, T-CELL; STEM CELL TRANSPLANTATION;

EID: 85014625466     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1365     Document Type: Article

References (32)

1. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHOclassification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010; 102: 83-7.
2. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-52.
3. Townsend W, Linch D. Hodgkin's lymphoma in adults. Lancet 2012; 380: 836-47.
4. Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol 2009; 647: 174-85.
5. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-21.
6. Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res 2012; 18: 2780-90.
7. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014; 65: 333-47.
8. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517-28.
9. Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology 2015; 4: e1027469.
10. Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol 2014; 155: 160-75.
11. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 T cells. J Exp Med 2005; 202: 907-12.
12. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13: 739-52.
13. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
14. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20: 221-30.
15. Engert A. Hodgkin's lymphoma: who needs consolidation treatment? Lancet 2015; 385: 1810-12.
16. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013; 1: 26-31.
17. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol 1999; 90: 157-64.
18. Cabrera CM, Urra JM, Carreno A, Zamorano J. Differential expression of CD30 on CD3 T lymphocytes in patients with systemic lupus erythematosus. Scand J Immunol 2013; 78: 306-12.
19. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cellmalignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33: 540-9.
20. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for theimmunotherapy of HER2-positive sarcoma. J Clin Oncol 2015; 33: 1688-96.
21. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
22. Liza John, Michael Kershaw, Phillip Darcy. Blockade of PD-1 immunosuppression boostsCART-cell therapy. Oncolmmunology 2013; 2: e26286.
23. Hasenclever D, Diehl V. Aprognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-14.
24. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233-39.
25. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, HwuP, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-4.
26. Ramakrishnan R., Assudani D., Nagaraj S., Hunter T, Cho HI, Antonia S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120: 1111-24.
27. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res 2011; 1: 482-97.
28. Carbone A, Gloghini A, Castagna L, Santoro A, Carlo-Stella C. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. J Pathol 2015; 237: 4-13.
29. Cader FZ, Vockerodt M, Bose S, Nagy E, Brundler MA, Kearns P, et al. The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. Blood 2013; 122: 4237-45.
30. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6: 583-92.
31. Benitez A, Yates TJ, Lopez LE, Cerwinka WH, Bakkar A, Lokeshwar VB. Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res 2011; 71: 4085-95.
32. Whatcott CJ, Han H, Posner RG, Hostetter G, Von Hoff DD. Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov 2011; 1: 291-6.